Ann: Quarterly Cashflow Report, page-11

Remuneration is one thing which has nothing to do with this report. I am sure all the readers will be voting against the obscenely high remuneration to CEO and Co......consideratng what happened 10 months ago *bse (black swan event)....and this is exactly the reason I will be voting no

I beg to differ @col69 re the quarterly cashflow report. It is not necessary to update activities......but Starpharma has

In respect of Dep Cabazitaxel........proof of concept was the catalyst for licensing drug.....this could be closer than shareholders imagine....it was reported in several announcements POC could be before phase 2 trials start........well according to today's announcement.....it is inferred dose escalation phase is almost complete (market sensitive is an understatement......once again....need to read between lines)

Once again here is the particular statement....

The dose escalation phase for DEP® cabazitaxel is approaching completion with multiple patients displaying efficacy signals, including stable disease of more than 47 weeks and significant reductions in specific tumour biomarkers, such as prostate specific antigen (PSA).

Regarding quarter on quarter sales.....it takes time for the snowball to gain momentum and turn into an unstoppable avalanche. I know....I have many years experience in sales and marketing.

I remain very confident and expect the woooooosh factor to come in before end of week